...III Jennerex Biotherapeutics Inc. JX-594 Recombinant vaccinia virus (TK-deletion plus GM-CSF) Liver cancer Ph II Neotropix Inc....

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate intravenous NTX-010 in 99 patients. Neotropix Inc....

...the Department of Virology at the University of Helsinki. Paul Hallenbeck, president and CSO of Neotropix Inc....
...are administered. At the levels we are delivering, the main concern is clearly liver toxicity." Neotropix's...
...Jennerex Biotherapeutics Inc. , San Francisco, Calif. Mayo Clinic College of Medicine , Rochester, Minn. Neotropix Inc....

...G207 HSV modified to produce a toxic metabolite in tumor cells Brain cancer Phase I Neotropix Inc....

...107 to 1011 vp/kg of intravenous NTX-010. The product has Orphan designation for neuroendocrine cancers. Neotropix Inc....

...FDA granted Orphan Drug designation for Neotropix's NTX-010 to treat neuroendocrine cancers. The naturally occurring oncolytic...
...neuroendocrine cancers. The naturally occurring oncolytic virus is in Phase I testing for the indication. Neotropix Inc....

...Phase I trial in 15 to 25 patients with various types of advanced neuroendocrine cancers. Neotropix Inc....

...stabilize transthyretin , a blood protein. Fidelity Biosciences also participated in the deal. Cancer company Neotropix...